Forskningsresultat

Vetenskapliga publikationer utförda med stöd från Johan Janssons stiftelse

Grundvetenskapliga publikationer

1. Svec D, Dolatabadi S, Thomsen C, Cordes N, Shannon M, Fitzpatrick P, Landberg G, Åman P, Ståhlberg A. Identification of inhibitors regulating cell proliferation and FUS-DDIT3 expression in myxiod liposarcoma using combined DNA, mRNA and protein analyzes. Laboratory Investigation, 2018, accepted.

2. Karlsson J, Kroneis T, Jonasson E, Larsson E*, Ståhlberg A. Transcriptomic characterization of the human cell cycle in individual unsynchronized cells. Journal of Molecular Biology, 2017, 429:3909-24.

3. Kroneis T, Jonasson E, Andersson D, Dolatabadi S, Ståhlberg A. Global preamplification simplifies targeted mRNA quantification. Scientific Reports, 2017, 7:45219.

4. Ståhlberg A, Krzyzanowski PM, Egyud M, Filges S, Stein L, Godfrey TE*. Simple multiplexed PCR-based barcoding of DNA for ultra-sensitive mutation detection by next-generation sequencing (SiMSen-Seq). Nature Protocols, 2017, 12:664-82.

5. Dolatabadi S, Candia J, Akrap N, Vannas C, Tesan Tomic T, Losert W, Landberg G, Åman P, Ståhlberg A. Cell cycle and cell size dependent gene expression reveals distinct subpopulations at single-cell level. Frontiers Genetics, 2017, 8:1.

6. Åman P, Dolatabadi S, Svec D, Jonasson E, Safavi S, Andersson D, Grundevik P, Thomsen C, Ståhlberg A. Regulatory mechanisms, expression levels and proliferation effects of the FUS-DDIT3 fusion oncogene in liposarcoma. Journal of Pathology, 2016, 238:689-99.

7. Safavi S, Järnum S, Vannas C, Udhane S, Jonasson E, Tomic TT, Grundevik P, Fagman H, Hansson M, Kalender Z, Jauhiainen A, Dolatabadi S, Wessel Stratford E, Myklebost O, Eriksson M, Stenman G, Schneider Stock R, Ståhlberg A, Åman P. HSP90 inhibition blocks ERBB3 and RET phosphorylation in myxoid/round cell liposarcoma and causes massive cell death in vitro and in vivo. Oncotarget, 2016, 7:433-45.

8. Andersson D, Akrap N, Svec D, Godfrey TE, Kubista M, Landberg G, Ståhlberg A. Properties of targeted preamplification in DNA and cDNA quantification. Expert Review in Molecular Diagnostics, 2015 15:1085-100.

9. Ståhlberg A, Kåbjörn Gustafsson C, Engtröm K, Thomsen C, Dolatabadi S, Jonasson E, Li CY, Ruff D, Chen SM, Åman P. Normal and functional TP53 in genetically stable myxoid/round cell liposarcoma. PLoS One, 2014, 9:e113110.

10. Kåbjörn Gustafsson C, Ståhlberg A, Engtröm K, Danielsson A, Turesson I, Aman P. Cell senescence in myxoid/round cell liposarcoma. Sarcoma, 2014, 2014:208786.

11. Svec D, Andersson D, Pekny M, Sjöback R, Kubista M, Ståhlberg A. Direct cell lysis for single-cell gene expression profiling. Frontiers Oncology, 2013, 3:274.

12. Thomsen C, Grundevik P, Elias P, Ståhlberg A, Åman P. A conserved N-terminal motif is required for complex formation between FUS, EWSR1, TAF15 and their oncogenic fusion proteins. FASEB Journal, 2013, 27:4965-74.

13. Ståhlberg A, Rusnakova V, Forootan A, Anderova M, Kubista M*. RT-qPCR work-flow for single-cell data analysis. Methods, 2013, 59:80-8.

14. Ståhlberg A, Thomsen C, Ruff D, Åman P. Quantitative PCR analysis of DNA, RNAs and proteins in the same single-cell. Clinical Chemistry, 2012, 58:1682-91.

15. Norrman K, Strömbeck A, Semb H, Ståhlberg A. Distinct Gene Expression Signatures in Human Embryonic Stem Cells Differentiated Towards Definitive Endoderm at Single-Cell Level. Methods, 2013, 59:59-70.

16. Jauhiainen A, Thomsen C, Strömbom L, Grundevik P, Andersson C, Danielsson A, Andersson MK, Nerman O, Rörkvist L, Ståhlberg A, Åman P. Distinct cytoplasmic and nuclear functions of the stress induced protein DDIT3/CHOP/GADD153. PLoS One, 2012, 7:e33208.

17. Thomsen C, Udhane S, Runnberg R, Wiche G, Ståhlberg A, Åman P. Fused in sarcoma (FUS) interacts with the cytolinker protein plectin: Implications for FUS subcellular localization and function. Experimental Cell Research, 2012, 318:653-661.

Kliniskt vetenskapliga publikationer

18. Hagberg, K., R. Brånemark, and O. Hägg, Questionnaire for Persons with a Transfemoral Amputation (Q-TFA): initial validity and reliability of a new outcome measure. J Rehabil Res Dev, 2004.

19. Hagberg, K., et al., Socket versus bone-anchored trans-femoral prostheses: hip range of motion and sitting comfort. Prosthet Orthot Int, 2005. 29(2): p. 153-63.

20. Hagberg, K., E. Haggström, and R. Brånemark, Physiological cost index (PCI) and walking performance in individuals with transfemoral prostheses compared to healthy controls. Disabil Rehabil, 2007. 29(8): p. 643-9.

21. Hagberg, K., et al., Osseointegrated trans-femoral amputation prostheses: prospective results of general and condition-specific quality of life in 18 patients at 2-year follow-up. Prosthet Orthot Int, 2008. 32(1): p. 29-41.

22. Hagberg, K., E. Hansson, and R. Brånemark, Outcome of Percutaneous Osseointegrated Prostheses for Patients With Unilateral Transfemoral Amputation at Two-Year Follow-Up. Arch Phys Med Rehabil, 2014.

23. Lennerås M, Tsikandylakis G, Trobos M, Omar O, Vazirisani F, Palmquist A, Berlin Ö, Brånemark R, Thomsen P. The clinical, radiological, microbiological, and molecular profile of the skin-penetration site of transfemoral amputees treated with bone-anchored prostheses. J Biomed Mater Res A. 2017 Feb;105(2):578-589. doi: 10.1002/jbm.a.35935. Epub 2016 Nov 7.

24. Tsikandylakis G, Berlin Ö, Brånemark R. Implant survival, adverse events, and bone remodeling of osseointegrated percutaneous implants for transhumeral amputees. Clin Orthop Relat Res. 2014 Oct;472(10):2947-56. doi: 10.1007/s11999-014-3695-6. PMID: 24879569

25. Brånemark R, Berlin Ö, Hagberg K, Bergh P, Gunterberg B, Rydevik B. A novel osseointegrated percutaneous prosthetic system for the treatment of patients with transfemoral amputation: A prospective study of 51 patients. Bone Joint J 2014;96‐b:106–113.

26. Jonatan Tillander, Kerstin Hagberg, Örjan Berlin, Lars Hagberg, Rickard Brånemark. Osteomyelitis risk in patients with transfemoral amputations treated with osseointegration prostheses. Clin Orthop Relat Res. 2017 Dec; 475(12): 3100–3108. Published online 2017 Sep 22. doi: 10.1007/s11999-017-5507-2

27. Hansson E, Hagberg K, Cawson M, Brodtkorp TH, “Patients with unilateral transfemoral amputation treated with percutaneous osseointegrated prostheses – a cost effectiveness analysis” Bone Joint J 2018;100-B: ?? Accepted 2017-11-28 in press March 2018

28. Hagberg, K. “Bone-anchored prostheses in patients with traumatic bilateral transfemoral amputations – rehabilitation description and outcome in 12 cases treated with the OPRA implant system”. Submitted to Disability and Rehabilitation: Assistive Technology, Dec 2017

Doktorsavhandlingar

Hagberg, K., Transfemoral Amputation, Quality of Life and Prosthetic Function. Studies focusing on individuals with amputation due to reasons other than peripheral vascular disease, with socket and osseointegrated prostheses., in Department of Orthopaedics, Institute of Clinical Sciences, The Sahlgrenska Academy. 2006, Göteborg University: Göteborg, Sweden.

Översiktsartiklar

Kubista M, Dreyer J, Ståhlberg A, The secrets of the cell. Molecular Aspects of Medicine, 2017, 59:1-4.

Ståhlberg A, Kubista M. Technical aspects and recommendations for single-cell qPCR. Molecular Aspects of Medicine, 2017, 59:28-35.

Ståhlberg A, Kubista M. The workflow of single-cell expression profiling using quantitative real-time PCR. Expert Review in Molecular Diagnostics. 2014, 14:323-31.

Ståhlberg A, Rusnakova V, Kubista M. The added value of single-cell gene expression profiling. Briefings in Functional Genomics, 2013, 12:81-89.

Ståhlberg A, Kubista M, Åman P. Single-cell gene-expression profiling and its potential diagnostic applications. Expert Review in Molecular Diagnostics, 2011, 11:735-740.

Totalt har stiftelsen under åren 1998 till 2017 delat ut 11,2 miljoner kronor till forskning.

DELA: